You are here: Industry Insights > clarity

News List

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics prnasia
December 03, 2021
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH)...
Fifty percent recruitment milestone for PROPELLER prostate cancer trial prnasia
December 02, 2021
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants...
Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial prnasia
July 29, 2021
Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate ...
Shaemus Gleason Appointed Executive Vice President US Operations at Clarity Pharmaceuticals prnasia
May 12, 2021
Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Shaemus Gleason as Executive Vice President U.S. Operations as the company expands its ...
Prof. Oliver Sartor Joins Clarity's Advisory Board prnasia
March 20, 2020
Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Prof. Oliver Sartor has joined Clarity's Advisory Board.
Merck's MS treatment shows promise in new data pharmatimes
May 03, 2018
New data published in The Multiple Sclerosis Journal has shown more promising results for Merck's MS treatment Mavenclad (cladribine tablets) on two subgroups of patients with highly active relapsing multiple sclerosis.
JN Medsys introduces new generation digital PCR system with greater sensitivity and the highest dete prnasia
December 04, 2017
JN Medsys, a life science company behind the high-throughput chip-based Clarity™ digital PCR system, today announced the launch of a new generation digital PCR system featuring more than 40,000 partitions and 4- to 6- colour detection channels.
Pharmaceutical R&D tax credit regulatory legislation: The need for clarity pharmafile
January 23, 2017
Since their introduction in the UK in 2000, R&D tax credits have provided a significant boost to pharmaceutical and biotech firms that are almost constantly engaged in product innovation and development. Figures released by the UK government in September